Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy, Hepatic Impairment
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Anaheim, California • Monterey Park, California • Tustin, California + 4 more

Conditions: Gestational Diabetes Mellitus as Antepartum Condition
Interventions: myo-inositol, Continuous glucose monitoring surveillance, Glucose monitoring; Dietary Supplement · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 13 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Impaired Fasting Glucose
Interventions: psyllium, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertriglyceridemia
Interventions: Epanova, Olive Oil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more

Conditions: Implantable Cardioverter-Defibrillator With Magnetic Resonance Imaging
Interventions: Patients with a ProMRI ICD System, Magnetic Resonance Imaging (MRI) scan; Device · Other
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nocturia
Interventions: Desmopressin Melt; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 64
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Diabetes Mellitus
Interventions: Adhesive glucose sensor, Pilocarpine; Device · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: San Diego, California

Conditions: Pain
Interventions: VX-708, Itraconazole, Midazolam, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Stage I Endometrial Adenocarcinoma, Uterine Cancer, Obesity
Interventions: Exercise on stationary recumbent exercise cycle, Health Education, Questionnaires, Neuroimaging, Genetic and Biomarkers; Behavioral · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: ACT-128800; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infections
Interventions: Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Reformulated OXY (Totowa) (oxycodone HCl), Reformulated OXY (Wilson) (oxycodone HCl); Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Smoking
Interventions: Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach., Nicotine Replacement Therapy, Varenicline, Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy); Behavioral · Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: COREG CR and lisinopril (FDC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Dietary Intervention, Fasting; Procedure · Other · Behavioral
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bioavailability
Interventions: Risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Fort Myers, Florida • Miramar, Florida • Austin, Texas

Conditions: Carbohydrate Metabolism
Interventions: CS- Beverage, CS+Fast, CS+Slow; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Healthy
Interventions: PL2200 fasted, PL2200 fed; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions: Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon, [1-13C] glucose, [2-13C] glucose; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Dietary Intervention, Magnetic Resonance Imaging, Vitamin C; Biological · Procedure · Other + 1 more
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Fullerton, California • Los Angeles, California

Conditions: Healthy, Impaired Glucose Tolerance
Interventions: Dietary supplement regimen, Dietary supplement and intermittent fasting regimen; Dietary Supplement · Other
Lead sponsor: Unicity International, Inc.; Industry
Eligibility: 30 Years to 69 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Addison, Illinois

Search by objective public record fields.

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Glycemic Impact of Myo-inositol in Pregnancy

Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

ProMRI Study of the Iforia ICD System (Phase C)

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Assisted Exercise in Obese Endometrial Cancer Patients

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Metabolism Informed Smoking Treatment: The MIST RCT

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

Neural and Metabolic Factors in Carbohydrate Reward

Food-Effect Pharmacokinetic Study of PL2200

Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability